CTHRepealedLegislation
Health Insurance (1997-98 Pathology Services Table) Regulations
Part 2Services and fees
Start here
Get a plain-English read of Part 2
Turn the raw legal text into a practical explanation grounded in Health Insurance (1997-98 Pathology Services Table) Regulations.
Part 2 Services and fees
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse"><thead><tr><td style="width:46.05pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Item</span></p></td><td colspan="2" style="width:244.45pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Pathology service</span></p></td><td colspan="2" style="width:46pt; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Fee</span><span> </span><span></span><span>($)</span></p></td></tr></thead><tbody><tr><td colspan="5" style="width:357.9pt; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top"><p class="TableColHead"><span>Group P1</span><span> </span><span>— Haematology</span></p></td></tr><tr><td style="width:48.85pt; border-top:0.75pt solid #000000; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65001</span></p></td><td colspan="2" style="width:247.25pt; border-top:0.75pt solid #000000; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, or reticulocyte count</span><span> </span><span>— 1 or 2 tests</span></p></td><td colspan="2" style="width:48.85pt; border-top:0.75pt solid #000000; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>7.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65003</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 65001, and calculation or measurement of cell index or indices</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>10.25</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65005</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination of blood film, or 5 part differential cell count, or both 5 part differential cell count and examination of blood film, including</span><br><span>(if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 65027; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>any of the following services:</span></p><p class="TableP2i" style="margin-bottom:3pt"><span style="width:25.87pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron;</span></p><p class="TableP2i"><span style="width:22.81pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>examination of a blood film with alpha-napthyl acetate esterase, chloroacetate esterase, neutrophil alkaline phosphatase, nitroblue tetrazolium, periodic acid Schiff or Sudan Black stains or acid elution stains</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>10.25</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65007</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Full blood examination (consisting of the services described in items 65003 and 65005)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65009</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Haemolysis or metabolic enzymes</span><span> </span><span>— assessment by:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte autohaemolysis test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte fragility test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>sugar water test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>erythrocyte metabolic enzyme test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>heat denaturation test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>isopropanol precipitation test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(g)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>acid haemolysis test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(h)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of muramidase in serum or urine;</span></p><p class="TableText"><span>1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>33.30</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65011</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Haemoglobinopathy, tests for the diagnosis of, consisting of haemoglobin electrophoresis and 2 of:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for HbH; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of HbA2; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>quantitation of HbF;</span></p><p class="TableText"><span>including a service described in item 65001, 65003, 65005 or 65007 (if performed)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>57.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65013</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Bone marrow trephine biopsy</span><span> </span><span>— histopathological examination of sections of bone marrow, including (if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination of aspirated material; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>special stains or immunochemical techniques (if any); and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 65001, 65003, 65005, 65007 or 65015</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>163.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65015</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Bone marrow</span><span> </span><span>— examination of aspirated material (including clot sections where necessary), including (if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>special stains or immunochemical techniques (if any); and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 65001, 65003, 65005 or 65007</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>82.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65017</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Blood grouping (including back-grouping if performed)</span><span> </span><span>— ABO and Rh (D antigen)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>9.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65019</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Blood grouping</span><span> </span><span>— Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system</span><span> </span><span>— 1 or more systems, including a service described in item 65017 (if performed)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65021</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>identification and quantitation of any antibodies detected; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>(if performed) a service described in item 65001, 65003, 65005 or 65007</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>36.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65023</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Compatibility tests</span><span> </span><span>— all tests performed on any</span><br><span>1 day, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>all grouping checks of patient and donor; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for antibodies, and, if necessary, quantitation of any antibodies detected; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 65001, 65003, 65005, 65007, 65017 or 65021 (if performed)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>99.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65025</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>20.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65027</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>1 or more of the following tests:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>direct Coombs test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>qualitative or quantitative test for cold agglutinins or heterophile antibodies;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>qualitative spectroscopic examination of blood for abnormal haemoglobins;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>8.95</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65029</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of: fibrinogen degradation products, fibrin monomer or D-dimer</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>12.40</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65031</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 65029</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>16.40</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65033</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 65029</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>20.40</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65035</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>4 or more tests described in item 65029</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.40</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65037</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation, by 1 or more techniques, of: plasminogen, antithrombin III, Protein C, Protein S, heparin cofactor II euglobulin clot lysis time and test for lupus anticoagulant</span><span> </span><span>— 1 to 3 tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>35.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65039</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>4 or more tests described in item 65037</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>80.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65041</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>55.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65043</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Heparin quantitation when monitoring a patient on subcutaneous heparin or low molecular weight heparin</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>32.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65045</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, or Passovy factor</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>48.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65047</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 65045</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>95.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65049</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 65045</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>140.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65052</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test) including any service described in item 65005 (if performed)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>10.25</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65053</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell surface antigens using flow cytometric methods including any service described in item 65007 or 65052 (if performed)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>34.00</span></p></td></tr><tr><td colspan="5" style="width:360.75pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P2</span><span> </span><span>— Chemical</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66201</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation in serum, plasma, urine or other body fluid, by any method except reagent tablet or reagent strip (with or without reflectance meter or electrophoresis) of: alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), calcium (total, dialysed or ionised), chloride, creatine kinase, creatine kinase isoenzymes (if not performed as described in item 66249), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, urate or urea</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>9.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66203</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>11.60</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66205</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.65</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>66207</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>4 tests described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>15.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>66209</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>5 tests described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="page-break-inside:avoid; page-break-after:avoid"><span>17.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66211</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6 or more tests described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66213</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Test by any method (except reagent strip or</span><br><span>dip-stick):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>for the presence of:</span></p><p class="TableP2i" style="margin-bottom:3pt"><span style="width:25.87pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>the following urine constituents</span><span> </span><span>— bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen; or</span></p><p class="TableP2i" style="margin-bottom:3pt"><span style="width:22.81pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>cryoglobulins or cryofibrinogen in plasma; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>of pH of body fluids other than urine (not including urine acidification test);</span></p><p class="TableText"><span>1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66215</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of cryoglobulins or cryofibrinogen following their detection in a test described in item 66213, including that service</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>20.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66223</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Osmolality, estimation by osmometer, in serum or in urine</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66225</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>blood gases (including pO</span><span style="font-size:7.33pt; vertical-align:sub">2</span><span style="vertical-align:-2pt">,</span><span> oxygen saturation and pCO</span><span style="font-size:7.33pt; vertical-align:sub">2</span><span>); and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>bicarbonate and pH;</span></p><p class="TableText"><span>including any other measurement (e.g. haemoglobin or potassium) or calculation performed on the same specimen</span><span> </span><span>— 1 or more tests on 1 specimen</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>33.25</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66227</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of blood gases, bicarbonate and pH as described in item 66225 on each specimen in excess of 1 to a maximum of 6 specimens within any 1 day</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>8.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66229</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Calculus, analysis of 1 or more</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>30.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66231</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>All qualitative and quantitative tests on blood, urine or other body fluid for:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>ingested or absorbed toxic chemicals;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:20.4pt; text-indent:0pt; display:inline-block"></span><span style="width:6.25pt; text-indent:0pt; display:inline-block"></span><span>including a service described in item 66235, 66237 or 66239 (if performed), but excluding:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the surveillance of sports people and athletes for performance improving substances; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the monitoring of patients participating in a drug abuse treatment program</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>41.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66235</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation, not elsewhere described in this Table by any method or methods, in blood or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>20.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66237</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>2 tests described in item 66235</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>28.65</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66239</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 66235</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>36.85</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66241</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Tests described in item 66235, if rendered under a request referred to in subparagraph (2)</span><span> </span><span>(a) (iii) of rule 6</span><span> </span><span>— each test to a maximum of 2 tests</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>8.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66243</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Amniotic fluid, spectrophotometric examination of, and quantitation of:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>lecithin/sphingomyelin ratio; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>palmitic acid, phosphatidylglycerol or lamellar body phospholipid;</span></p><p class="TableText"><span>1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>32.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66247</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Electrophoresis</span><br><span>(including quantitation), of serum and either or both urine or other body fluid all collected within a 28 day period, to demonstrate protein classes or presence of paraprotein, including the preliminary quantitation of:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>total protein, albumin and globulin; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>total relevant enzyme activity;</span></p><p class="TableText"><span>2 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>49.85</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66249</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Electrophoresis, quantitative or qualitative, of serum, urine or other body fluid to demonstrate:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>protein classes; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>presence and amount of paraprotein; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase;</span></p><p class="TableText"><span>including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>35.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66250</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Electrophoresis, quantitation or qualitative, of serum, for demonstration of lipoprotein subclasses, if the cholesterol is >6.5</span><span> </span><span>mmol/l and triglyceride >3.0</span><span> </span><span>mmol/l or in the diagnosis of types III and IV hyperlipidaemia</span><span> </span><span>— each episode to a maximum of</span><br><span>2 episodes in a 12 month period</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>30.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66255</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Alpha-1-acid glycoprotein, alpha-1-antitrypsin, or alpha-2-macroglobulin</span><span> </span><span>— quantitation in serum, urine or other body fluid</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66257</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>C-1 esterase inhibitor</span><span> </span><span>— quantitation</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66258</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>C-1 esterase inhibitor</span><span> </span><span>— functional assay</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>44.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66261</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>CA-125 antigen, CA-15.3 antigen, CA-19.9 antigen, carcinoembryonic antigen (CEA), mammary serum antigen, mucin-like carcinoma-associated antigen (1 or more fractions), neuron-specific enolase, or thyroglobulin in serum or other body fluid, in the monitoring or confirmation of malignancy</span><span> </span><span>— quantitation</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66262</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66261</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>36.65</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66263</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Iron studies, consisting of quantitation of:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>serum iron;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>transferrin or iron binding capacity; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>ferritin</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>36.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66265</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Serum B</span><span style="font-size:7.33pt; vertical-align:sub">12</span><span> or serum folate</span><span> </span><span>— 1 or more tests within a 28 day period</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66267</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Red cell folate and serum B</span><span style="font-size:7.33pt; vertical-align:sub">12</span><span>, and, if required, serum folate, to a maximum of 3 episodes in a 12 month period</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>44.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66269</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Vitamins</span><span> </span><span>— quantitation of vitamins A, B</span><span style="font-size:7.33pt; vertical-align:sub">1</span><span>, B</span><span style="font-size:7.33pt; vertical-align:sub">2</span><span>, B</span><span style="font-size:7.33pt; vertical-align:sub">3</span><span>, B</span><span style="font-size:7.33pt; vertical-align:sub">6</span><span>, C, and E in blood, urine or other body fluid</span><span> </span><span>— 1</span><span> </span><span>or more tests within a 6 month period</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>30.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66271</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Vitamin D or D fractions</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>37.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66277</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of aluminium (except if item 66325 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, or strontium, in blood, urine or other body fluid or tissue</span><span> </span><span>— 1 or more tests in a 6 month period</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>35.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66279</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Blood lead quantitation (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period</span><span> </span><span>— each test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>30.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66281</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Porphyrins (1 or more fractions), catecholamines</span><br><span>(1 or more fractions), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), or phenylacetic acid (PAA)</span><span> </span><span>— quantitation</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>39.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66283</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>faecal fat; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>breath hydrogen in response to loading with disaccharides;</span></p><p class="TableText"><span>1 or more tests within a 28 day period</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>39.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66285</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Enzymes</span><span> </span><span>— quantitation of 1 or 2 in solid tissue or tissues other than blood elements</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>39.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66287</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of 3 to 5 enzymes as described in</span><br><span>item 66285</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66289</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of 6 or more enzymes as described in</span><br><span>item 66285</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>97.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66293</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and quantitation of hormones</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>54.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66295</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Personal performance by a recognised pathologist of 1 or more of the following:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>growth hormone suppression by glucose loading;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>growth hormone stimulation by exercise;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>dexamethasone suppression test;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>L-dopa stimulation of growth hormone</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>50.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66297</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Personal performance by a recognised pathologist of 1 of the following:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>gonadotrophin releasing hormone stimulation test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>synacthen stimulation test;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>glucagon stimulation test with C-peptide measurement;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pentagastrin stimulation of thyrocalcitonin release;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>secretin stimulation of gastrin release;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>insulin hypoglycaemia;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(g)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>arginine infusion</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>80.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66299</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Personal performance by a recognised pathologist of 2 or more tests described in item 66297</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>140.00</span></p><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66315</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>78.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66317</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of HDL cholesterol or apolipoprotein B/A1 ratio in a patient who:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>has a serum cholesterol level >5.5</span><span> </span><span>mmol/l; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>has a fasting serum triglyceride level >2.0</span><span> </span><span>mmol/l; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is on a lipid lowering drug prescribed by a medical practitioner;</span></p><p class="TableText" style="margin-bottom:6pt"><span>each episode to a maximum of 4 episodes in a 12</span><span> </span><span>month period</span></p><p class="TableText"><span>(Item is subject to rule 9)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>12.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66319</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of glycosylated haemoglobin performed in the management of established diabetes</span><span> </span><span>— each test to a maximum of 4 tests in a 12 month period</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>16.60</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66321</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation, in the 2nd trimester of pregnancy, of alpha fetoprotein, human chorionic gonadotrophin, oestriol and any other substance to detect foetal abnormality, including a service described in 1 or more of items 66353, 66373, 73527 and 73529 (if performed)</span><span> </span><span>— 1 patient episode in a pregnancy</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>54.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66322</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of glycosylated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant</span><span> </span><span>— each test to a maximum of 6 tests in a 12 month period which includes the whole pregnancy, including a service in item 66319 (if performed)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>16.60</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66323</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>11.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66325</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum aluminium in a patient in a renal dialysis program</span><span> </span><span>— each test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>35.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66327</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>TSH quantitation</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>31.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66329</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Thyroid function tests (comprising the service described in item 66327 and 1 or more of the following tests</span><span> </span><span>— estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) in respect of a patient, if at least one of the following conditions is satisfied:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has an abnormal level of TSH;</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>41.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the tests are performed for the purpose of:</span></p><p class="TableP2i" style="margin-bottom:3pt"><span style="width:25.87pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>monitoring thyroid disease in the patient; or</span></p><p class="TableP2i"><span style="width:22.81pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>if the patient is an admitted</span><br><span>patient</span><span> </span><span>— investigating the sick euthyroid syndrome; or</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableP2i" style="margin-bottom:3pt"><span style="width:19.76pt; text-indent:0pt; display:inline-block"></span><span>(iii)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>investigating dementia or psychiatric illness of the patient; or</span></p><p class="TableP2i" style="margin-bottom:3pt"><span style="width:20.37pt; text-indent:0pt; display:inline-block"></span><span>(iv)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>investigating amenorrhoea or infertility of the patient;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the medical practitioner who requested the tests suspects the patient has pituitary dysfunction;</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient is on drugs that interfere with thyroid hormone metabolism or function</span></p><p class="TableText"><span>(Item is subject to rule 10)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66331</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation (except by reagent strip with or without reflectance meter or electrophoresis) of cholesterol or triglycerides or both in serum, plasma, urine or other body fluid</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>11.40</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66335</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>A service described in item 66331 and 1 test described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.65</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66337</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>A service described in item 66331 and 2 tests described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>15.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66339</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>A service described in item 66331 and 3 tests described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66341</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>A service described in item 66331 and 4 or more tests described in item 66201</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66343</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>participating in a drug abuse treatment program; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>being treated for drug effects;</span></p><p class="TableText"><span>including all tests on blood, urine or other body fluid</span><span> </span><span>— each episode, to a maximum of 21</span><span> </span><span>episodes in a 12 month period</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>23.80</span></p><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66353</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation in serum or other body fluids of alpha fetoprotein, except if requested as part of item</span><span> </span><span>66321</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66355</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Ferritin</span><span> </span><span>— quantitation, except if requested as part of iron studies</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66357</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Prostate specific antigen or prostatic acid phosphatase</span><span> </span><span>— quantitation in the confirmation or monitoring of malignancy</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66359</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66357</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>36.65</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66361</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Beta-2-microglobulin, caeruloplasmin, haptoglobins, microalbumin in proven diabetes mellitus, or prealbumin</span><span> </span><span>— quantitation in serum, urine or other body fluids</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66363</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66361</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>36.65</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66367</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of acetoacetate, alcohol, amino acids, ammonia, angiotensin converting enzyme,</span><br><span>beta-hydroxybutyrate, cholinesterase, cysteine, total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline (except if performed as part of item 66425 or 66426), lactate, oxalate, pyruvate, serotonin, xylose, or zinc</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66369</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 or more tests described in item 66367</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>38.30</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66373</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Human placental lactogen or oestriol</span><span> </span><span>— quantitation, except if requested as part of item 66321</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>31.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66375</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 66373</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>42.60</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66405</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation of hormones and hormone binding proteins</span><span> </span><span>— ACTH, aldosterone, androstenedione,</span><br><span>C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(lgF1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone)</span><span> </span><span>— 1 test</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>31.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66407</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>2 tests described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>42.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66409</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>3 tests described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>53.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66411</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>4 tests described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>64.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66413</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>5 tests described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>75.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66415</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6 or more tests described in item 66405</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>86.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66417</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Tests described in item 66405, if rendered under a request referred to in subparagraph (2)</span><span> </span><span>(a) (iii) of rule</span><span> </span><span>6</span><span> </span><span>— each test to a maximum of 5 tests</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>11.05</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66419</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Oral glucose tolerance test for the diagnosis of diabetes mellitus that includes the following:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>administration of glucose;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 3 estimations of blood glucose;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>if performed, any test described in item 66405</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66421</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Test for reducing substances in faeces by any method (except reagent strip or dipstick)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66422</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an immunological method; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a chemical method (except reagent strip or dip stick);</span></p><p class="TableText"><span>with a maximum of 3 examinations on specimens collected on separate days in a 28 day period</span><span> </span><span>— 1</span><span> </span><span>examination by both methods</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>8.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66423</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 examinations by both methods described in item 66422 performed on separately collected and identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.60</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66424</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 examinations by both methods described in item 66422 performed on separately collected and identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>26.40</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66425</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of products of collagen breakdown for the monitoring of patients with proven low bone mineral density, and if performed, a service described in item 66367</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66426</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of products of collagen breakdown for the monitoring of patients with metabolic bone disease, and if performed, a service described in item 66367</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66427</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66327 and 1 test described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>42.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66428</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66327 and 2 tests described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>53.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66429</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66327 and 3 tests described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>64.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66430</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66327 and 4 tests described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>75.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66431</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>TSH quantitation described in item 66327 and 5 tests described in item 66405</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>86.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66432</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Tests described in items 66327 and 66405, if rendered under a request mentioned in subparagraph 2 (a) (iii) of rule 6</span><span> </span><span>— each test to a maximum of 5 tests</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>11.05</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>66435</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Detection of the C282Y genetic mutation for haemochromatosis where:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient has a first degree relative with haemochromatosis or with homozygosity for the C282Y genetic mutation;</span></p><p class="TableText" style="margin-bottom:6pt"><span>not exceeding 1 episode in a 3 year period</span></p><p class="TableText"><span>(Item is subject to rule 22)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>36.00</span></p></td></tr><tr><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P3</span><span> </span><span>— Microbiology</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69201</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>differential cell count (if performed); or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination for dermatophytes; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>dark ground illumination; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>stained preparation or preparations, using any relevant stain or stains;</span></p><p class="TableText"><span>1 or more tests</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>8.15</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69205</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Culture and (if performed) microscopy to detect pathogenic micro-organisms (including fungi but excluding viruses), from nasal swabs, throat swabs, eye swabs and ear swabs, including (if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere described in this Table; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69201;</span></p><p class="TableText"><span>specimens from 1 or more sites</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>21.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69207</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy and culture to detect pathogenic</span><br><span>micro-organisms, including fungi but excluding viruses, from:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens); or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>specimens of sputum (except when part of item 69213);</span></p><p class="TableP1a" style="margin-bottom:3pt"><span>including (if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this Table; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogenic identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in items 69201, 69205 and 73810;</span></p><p class="TableText"><span>1 or more tests on 1 or more specimens</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>33.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69209</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Microscopy and culture of postoperative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic culture and the use of different culture media, and including (if performed):</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>47.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of antigens not elsewhere specified in this Table; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69201, 69205 or 69207;</span></p><p class="TableText"><span>specimens from 1 or more sites</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69213</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy with appropriate stains and culture of</span><br><span>3 specimens of sputum, urine or other body fluids for mycobacteria including (if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>microscopy and culture of other bacterial </span><span style="width:16.28pt; text-indent:0pt; display:inline-block"></span><span>pathogens; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69201</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>125.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69217</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Urine examination (including serial examination) by any means other than simple culture by dip slide, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>cell count; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>culture; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>colony count (if performed); and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>stained preparations; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>identification of cultured pathogens; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>antibiotic susceptibility testing; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(g)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>any examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>20.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69219</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Detection of:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus respiratory syncytial virus, cryptococcal antigens or Varicella zoster; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Clostridium difficile toxin (except if a service described in items 69289 to 69291 has been performed);</span></p><p class="TableText"><span>1 or more tests</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>25.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69223</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of herpes simplex virus from material obtained directly from a patient (not cultures)</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>10.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69229</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in the Schedule</span><span> </span><span>— 1 test</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69231</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 69229</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69233</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 tests described in item 69229</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>34.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69235</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>4 tests described in item 69229</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>44.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69237</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>5 tests described in item 69229</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>54.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span></span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69239</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6 or more tests described in item 69229</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>64.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69241</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Tests described in item 69229, if rendered under a request referred to in subparagraph (2)</span><span> </span><span>(a) (iii) of rule 6 </span><span></span><span>— each test to a maximum of 5 tests</span></p><p class="TableText"><span>(Item is subject to rule 6)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>10.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69251</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Antibiotics or antimicrobial chemotherapeutic agents in serum, urine or other body</span><br><span>fluid</span><span> </span><span>— quantitation</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69253</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 1 of the following: rubella immune status, specific syphilis serology, hepatitis B surface antigen; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in 1 or more of items 69229, 69266 to 69273, 69275 to 69278, 69280 and 69281 (if performed)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69255</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of 2 of the following: rubella immune status, specific syphilis serology or hepatitis B surface antigen;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in 1 or more of items 69229, 69266 to 69273, 69275 to 69278, 69280 and 69281 (if performed)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69257</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the determination of all 3 of the following: rubella immune status, specific syphilis serology and hepatitis B surface antigen; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in 1 or more of items 69229, 69266 to 69273, 69275 to 69278, 69280 and 69281 (if performed)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>34.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69259</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation of HIV viral RNA load in plasma, serum or cerebrospinal fluid in the monitoring of a HIV sero-positive patient, who is not on antiretroviral therapy</span><span> </span><span>— 1</span><span> </span><span>or more assays on 1 or more specimens in any 1 episode to a maximum of 6 episodes in a 12 month period</span></p><p class="TableText"><span>(Item is subject to rule 20)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>176.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69260</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Quantitation of HIV viral RNA load in plasma, serum or cerebrospinal fluid in the monitoring of antiretroviral therapy in a HIV sero-positive patient</span><span> </span><span>— 1 or more assays on 1 or more specimens</span><br><span>in any 1 episode to a maximum of 6 episodes in a 12</span><span> </span><span>month period</span></p><p class="TableText"><span>(Item is subject to rule 20)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>176.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69262</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of Chlamydia by any method in specimens from 1 or more sites</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.85</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69264</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination for Herpes simplex virus of 1</span><span> </span><span>or more types by culture in material obtained directly from a patient, including a service described in items</span><span> </span><span>69223, 69262 or 69282 (if performed)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>28.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69266</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute Hepatitis A using:</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:20.4pt; text-indent:0pt; display:inline-block"></span><span style="width:6.25pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis A IgM antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69267</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Determination of immune status to Hepatitis A using:</span></p><p class="TableText" style="margin-bottom:6pt"><span style="width:28.35pt; display:inline-block"></span><span>Hepatitis A IgG antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69268</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute or resolving Hepatitis B, or testing of close, recent contacts of proven Hepatitis B infection, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B e antibody test (if the Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive) (if performed)</span></p><p class="TableText"><span>(Item is subject to rule</span><span> </span><span>12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69269</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for resolution of Hepatitis B if the Hepatitis B core antibody test is positive and the Hepatitis B surface antigen test is negative, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>34.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69270</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis B (post exposure) using:</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:20.4pt; text-indent:0pt; display:inline-block"></span><span style="width:6.25pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis B core antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69271</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis B (post vaccination) using:</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:20.4pt; text-indent:0pt; display:inline-block"></span><span style="width:6.25pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis B surface antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69272</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for chronic Hepatitis B or determination of carriage of Hepatitis B antigen using:</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:20.4pt; text-indent:0pt; display:inline-block"></span><span style="width:6.25pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis B surface antigen test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69273</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for chronic Hepatitis B or carriage of Hepatitis B antigen if the Hepatitis B surface antigen test is positive, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B e antigen test</span></p><p class="TableText"><span>(Item is subject to rule</span><span> </span><span>12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69274</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Testing for Hepatitis C using:</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:20.4pt; text-indent:0pt; display:inline-block"></span><span style="width:6.25pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis C antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69275</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute or chronic Hepatitis D in a patient with a positive Hepatitis B surface antigen test using:</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:20.4pt; text-indent:0pt; display:inline-block"></span><span style="width:6.25pt; text-indent:0pt; display:inline-block"></span><span>Hepatitis D antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>13.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69276</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis A and Hepatitis B, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A IgG antibody test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test or Hepatitis B surface antibody test</span></p><p class="TableText"><span>(Item is subject to rule</span><span> </span><span>12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69277</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for chronic viral hepatitis, or Hepatitis B or Hepatitis C carriage, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test</span></p><p class="TableText"><span>(Item is subject to rule</span><span> </span><span>12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69278</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for chronic viral hepatitis, or Hepatitis B or Hepatitis C carriage, if Hepatitis B surface antigen test is positive, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B e antigen test</span></p><p class="TableText"><span>(Item is subject to rule</span><span> </span><span>12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>34.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69279</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute Hepatitis A, Hepatitis B, Hepatitis C and Hepatitis D in a patient with a currently elevated transaminase level, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A IgM antibody test; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B surface antigen test; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(e)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B e antibody test (if Hepatitis B surface antigen test is negative and Hepatitis</span><span> </span><span>B core antibody test is positive) (if performed); and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:9.41pt; text-indent:0pt; display:inline-block"></span><span>(f)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis D antibody test (if Hepatitis B surface antigen test is positive) (if performed)</span></p><p class="TableText"><span>(Item is subject to rule</span><span> </span><span>12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>44.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69280</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Determination of immune status to Hepatitis B and testing for Hepatitis C, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis B core antibody test or Hepatitis B surface antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69281</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Syphilis serology and any 1 of items 69273, 69274 or 69277</span></p><p class="TableText"><span>(Item is subject to rule</span><span> </span><span>12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>34.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69282</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Microscopy and culture to detect pathogenic micro-organisms, including the detection of Chlamydia by any method from urethra, vagina, cervix or rectum and including (if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of microbial antigens; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item</span><span> </span><span>69201, 69205, 69207, 69223, 69262, 69264 or 73810;</span></p><p class="TableText"><span>1 or more tests on 1 or more specimens</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>56.15</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69283</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Investigation for acute Hepatitis A and Hepatitis C in a patient with a currently elevated transaminase level, including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis A IgM antibody test; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>Hepatitis C antibody test</span></p><p class="TableText"><span>(Item is subject to rule 12)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>27.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69284</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient is Hepatitis C sero</span><span>‑</span><span>positive and has normal liver function tests on 2</span><span> </span><span>occasions 6</span><span> </span><span>months apart;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the patient’s serological status is uncertain after testing;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the test is performed for the purpose of:</span></p><p class="TableP2i" style="margin-bottom:3pt"><span style="width:25.87pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or</span></p><p class="TableP2i" style="margin-bottom:6pt"><span style="width:22.81pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.15pt; text-indent:0pt; display:inline-block"> </span><span>the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient;</span></p><p class="TableText" style="margin-bottom:6pt"><span>not exceeding 1 episode in a 12 month period</span></p><p class="TableText"><span>(Item is subject to rule 21)</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>64.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69285</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Microscopy of faeces for parasites using concentration techniques (including the use of appropriate stains) with a maximum of</span><br><span>3 examinations on specimens collected on separate days, including a service (if performed) described in item 69201</span><span> </span><span>— 1 examination</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>16.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69286</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 examinations described in item 69285 performed on separately collected and identified specimens</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>32.40</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69287</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 examinations described in item 69285 performed on separately collected and identified specimens</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>48.60</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69289</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Culture of faeces for faecal pathogens, using at least 2</span><span> </span><span>selective or enrichment media and culture in at least 2 different atmospheres including (if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>pathogen identification and antibiotic susceptibility testing; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the detection of clostridial toxins or antigens not elsewhere specified in this Table; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a service described in item 69201;</span></p><p class="TableText"><span>with a maximum of 3 examinations performed on separately collected and identified specimens in any 7</span><span> </span><span>day period</span><span> </span><span>— 1 examination</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>51.65</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69290</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 examinations described in item 69289 performed on separately collected and identified specimens</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>103.30</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69291</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 examinations described in item 69289 performed on separately collected and identified specimens</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>154.95</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69293</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>identification of any cultured pathogen; and</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>necessary antibiotic susceptibility testing;</span></p><p class="TableText"><span>to a maximum of 3 sets of cultures</span><span> </span><span>— 1 set of cultures</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>30.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69294</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 sets of cultures described in item 69293</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>60.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>69295</span></p></td><td style="width:240.15pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 sets of cultures described in item 69293</span></p></td><td colspan="3" style="width:55.95pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>90.00</span></p></td></tr><tr><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P4</span><span> </span><span>— Immunology</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71061</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Immunoelectrophoresis or immunofixation, of serum, urine or other body fluid, and characterisation of, a paraprotein or cryoglobulin not previously characterised, including a service described in 1 or both of items 66213 and 66215 (if performed)</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>28.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71063</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Immunoelectrophoresis or immunofixation of serum and urine concurrently collected, and characterisation of, a paraprotein not previously characterised</span><span> </span><span>— 2 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>43.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71065</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of CSF and serum concurrently collected for the presence of oligoclonal proteins</span><span> </span><span>— 2 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>43.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71067</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of total immunoglobulins A, G, M or D by any method in serum, urine or other body fluid</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>14.85</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71069</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71067</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>23.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71071</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71067</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>32.05</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71073</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of all 4 immunoglobulin G</span><span> </span><span>subclasses</span><span> </span><span>— each patient episode</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>104.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71075</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of immunoglobulin E (total), with a maximum of 2 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>26.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71077</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of immunoglobulin E (total) in the follow-up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6</span><span> </span><span>patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>26.70</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71079</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>24.10</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71081</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of total haemolytic complement</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71083</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of complement components C3 and C4 or properdin factor B</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71085</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71083</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>28.55</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71087</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71083</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>37.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71089</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule</span><span> </span><span>— 1 test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>28.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71091</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71089</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>52.10</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71093</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71089</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>75.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71095</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3</span><span> </span><span>assays in 1</span><span> </span><span>year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>40.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71097</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Antinuclear antibodies</span><span> </span><span>— detection in serum or other body fluids, including quantitation if required</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>25.10</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71099</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Double-stranded DNA antibodies</span><span> </span><span>— quantitation by 1</span><span> </span><span>or more methods other than the Crithidia method</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>26.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71101</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Antibodies to 1 or more extractable nuclear antigens</span><span> </span><span>— detection in serum or other body fluids</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.15</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71103</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Characterisation of an antibody detected in a service described in item 71101 (including that service)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>51.35</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71106</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Rheumatoid factor</span><span> </span><span>— detection by any technique in serum or other body fluids, including quantitation if required</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>11.15</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71109</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor)</span><span> </span><span>— detection, including quantitation if required, of 1 antibody</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>34.10</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71113</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies described in item 71109</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>46.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71115</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of 3 antibodies described in item 71109</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>59.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71117</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of 4 antibodies described in item 71109</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71119</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Antibodies to tissue antigens not elsewhere specified in this Table</span><span> </span><span>— detection, including quantitation if required, of 1 antibody</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.10</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71121</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of 2 antibodies specified in item 71119</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>20.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71123</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of 3 antibodies specified in item 71119</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>23.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71125</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Detection of 4 or more antibodies specified in item 71119</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>27.30</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71127</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Functional tests for lymphocytes</span><span> </span><span>— quantitation other than by microscopy of:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>proliferation induced by 1 or more mitogens; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>proliferation induced by 1 or more antigens; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>estimation of 1 or more mixed lymphocyte reactions;</span></p><p class="TableText"><span>including a test described in item 65005 (if performed), with a maximum of 2 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>174.05</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71129</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 71127</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>215.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71131</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 71127</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>255.95</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71135</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Quantitation of neutrophil function, comprising at least 2 of the following:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>chemotaxis;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>phagocytosis;</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>oxidative metabolism;</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>bactericidal activity;</span></p><p class="TableText"><span>including any test described in item 65005 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in a</span><br><span>12 month period</span><span> </span><span>— each patient episode</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>205.25</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71137</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7</span><span> </span><span>antigens, with a maximum of 2 patient episodes in a 12 month period</span><span> </span><span>— each patient episode</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>29.85</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71139</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>102.65</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71141</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>194.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71143</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>256.60</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71145</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>418.95</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71147</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>HLA-B27 typing</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>32.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71149</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including a service described in item 71147 (if performed)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>106.85</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>71151</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes)</span><span> </span><span>— phenotyping or genotyping of 2</span><span> </span><span>or more antigens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>117.30</span></p></td></tr><tr><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P5</span><span> </span><span>— Tissue pathology</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72813</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1 or more separately identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>79.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72816</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1 separately identified specimen</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>84.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72817</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 2 or more separately identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>94.50</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72823</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1 separately identified specimen</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>95.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72824</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 2 to 4 separately identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>105.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72825</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 5 or more separately identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>115.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72830</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1 or more separately identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>125.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72836</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions</span><span> </span><span>— 1 or more separately identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>150.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72846</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 antibodies</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>30.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72847</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 4 or more antibodies</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>40.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72851</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Electron microscopic examination of biopsy material</span><span> </span><span>— 1</span><span> </span><span>separately identified specimen</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>150.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72852</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Electron microscopic examination of biopsy material</span><span> </span><span>— 2 or more separately identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>200.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72855</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Intraoperative frozen section diagnosis of biopsy material</span><span> </span><span>— 1 separately identified specimen</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>150.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>72856</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Intraoperative frozen section diagnosis of biopsy material</span><span> </span><span>— 2 or more separately identified specimens</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>200.00</span></p></td></tr><tr><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P6</span><span> </span><span>— Cytology</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73043</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>19.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73045</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053); and including any Group P5 service, if performed on:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>specimens resulting from washings or brushings from sites not specified in item 73043; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a single specimen of sputum or urine; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>1 or more specimens of other body fluids;</span></p><p class="TableText"><span>1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>45.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73047</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Cytology of a series of 3 sputum or urine specimens for malignant cells</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>90.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73049</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>65.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73051</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues if:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the aspiration is performed by a recognised pathologist; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a recognised pathologist attends the aspiration and performs cytological examination during the attendance</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>163.85</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73053</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Cytology of smears from cervix:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>due to an unsatisfactory smear taken in the circumstances defined in para (a) above; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>if there is inadequate information provided to use item 73055;</span></p><p class="TableText"><span>each examination</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73055</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Cytology not associated with item 73053, of smears from cervix in association with:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the management of previously detected abnormalities including precancerous or cancerous conditions; or</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia;</span></p><p class="TableText"><span>each test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73057</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Cytology of smears from vagina, not associated with item 73053 or 73055 nor to monitor hormone replacement therapy</span><span> </span><span>— each test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>17.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73059</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 1 to 3 antibodies</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>30.00</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73060</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen</span><span> </span><span>— 4 or more antibodies</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>40.00</span></p></td></tr><tr><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group</span><span style="font-size:6pt; vertical-align:super"> </span><span>P7</span><span> </span><span>— Cytogenetics</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73287</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of one or more of any tissue or fluid except blood</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>327.60</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73289</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of blood</span><span> </span><span>— 1 or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>296.85</span></p></td></tr><tr><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P8</span><span> </span><span>— Infertility and pregnancy tests</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73521</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Semen examination for presence of spermatozoa, or examination of cervical mucus for spermatozoa (Huhner’s test)</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73523</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:3pt"><span>Semen examination (other than post-vasectomy semen examination), including:</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>measurement of volume, sperm count, and motility; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>examination of stained preparations; and</span></p><p class="TableP1a" style="margin-bottom:3pt"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>morphology; and (if performed)</span></p><p class="TableP1a" style="margin-bottom:6pt"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>differential count and 1 or more chemical tests;</span></p><p class="TableText"><span>with a maximum of 4 episodes in a 12 month period</span><span> </span><span>— each episode</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>35.80</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73525</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Sperm antibodies</span><span> </span><span>— sperm-penetrating ability</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>18.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73527</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Chorionic gonadotrophin (beta-HCG)</span><span> </span><span>—</span><span> </span><span>detection in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy</span><span> </span><span>— 1</span><span> </span><span>or more tests</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>9.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73529</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Chorionic gonadotrophin (beta-HCG)</span><span> </span><span>— quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of hydatidiform mole, HCG-secreting neoplasm, or threatened abortion, or follow-up of abortion or diagnosis of ectopic pregnancy, including any services performed in 73527</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>28.25</span></p></td></tr><tr style="height:12.9pt"><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P9</span><span> </span><span>— Simple basic pathology tests</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73801</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Semen examination for presence of spermatozoa</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73802</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count</span><span> </span><span>— 1</span><span> </span><span>test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>4.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73803</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2 tests described in item 73802</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6.20</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73804</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>3 or more tests described in item 73802</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>7.95</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73805</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Microscopy of urine whether stained or not, or catalase test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>4.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73806</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Pregnancy test by 1 or more immunochemical methods</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>9.90</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73807</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Microscopy for wet film other than urine, including any relevant stain</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73808</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>8.45</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73809</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>2.30</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73810</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Microscopy for fungi in skin, hair or nails</span><span> </span><span>— 1 or more sites</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>6.75</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73811</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Mantoux test</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>10.95</span></p></td></tr><tr><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P10</span><span> </span><span>— Patient episode initiation</span></p></td></tr><tr><td style="width:48.75pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>73901</span></p></td><td colspan="2" style="width:247.15pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory</span></p></td><td style="width:47.2pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>7.95</span></p></td><td style="vertical-align:top"></td></tr><tr><td style="width:48.75pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>73903</span></p></td><td colspan="2" style="width:247.15pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of</span><span> </span><span>1 or more services described in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 from a person who is an in-patient of a hospital other than a recognised hospital</span></p></td><td style="width:47.2pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>14.15</span></p></td><td style="vertical-align:top"></td></tr><tr><td style="width:48.75pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>73905</span></p></td><td colspan="2" style="width:247.15pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital</span></p></td><td style="width:47.2pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>7.85</span></p></td><td style="vertical-align:top"></td></tr><tr><td style="width:48.75pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>73907</span></p></td><td colspan="2" style="width:247.15pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in</span><br><span>Group P9) if the specimen is collected in a licensed collection centre</span></p></td><td style="width:47.2pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>16.55</span></p></td><td style="vertical-align:top"></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73909</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>16.55</span></p></td></tr><tr><td style="width:48.75pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>73910</span></p></td><td colspan="2" style="width:247.15pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903 or 73905, or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing</span></p></td><td style="width:47.2pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>10.15</span></p></td><td style="vertical-align:top"></td></tr><tr><td style="width:48.75pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>73912</span></p></td><td colspan="2" style="width:247.15pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903 or 73905, or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a nursing home or institution</span></p></td><td style="width:47.2pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>10.15</span></p></td><td style="vertical-align:top"></td></tr><tr><td style="width:48.75pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>73913</span></p></td><td colspan="2" style="width:247.15pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or 73907 or items in Group P9) if the specimen is collected from the person by the person</span></p></td><td style="width:47.2pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>10.15</span></p></td><td style="vertical-align:top"></td></tr><tr><td style="width:48.75pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>73915</span></p></td><td colspan="2" style="width:247.15pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>Initiation of a patient episode by collection of a specimen for a service (other than a service described in items 73901, 73903 or 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner</span></p></td><td style="width:47.2pt; padding-right:4pt; padding-left:4pt; vertical-align:top"><p class="TableText"><span>10.15</span></p></td><td style="vertical-align:top"></td></tr><tr><td colspan="5" style="width:360.7pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableColHead"><span>Group P11</span><span> </span><span>— Specimen referred</span></p></td></tr><tr><td style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>73921</span></p></td><td colspan="2" style="width:247.25pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText" style="margin-bottom:6pt"><span>Receipt of specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another approved pathology authority</span></p><p class="TableText"><span>(Item is subject to subrule 15</span><span> </span><span>(9))</span></p></td><td colspan="2" style="width:48.85pt; padding-right:3.95pt; padding-left:3.95pt; vertical-align:top"><p class="TableText"><span>10.15</span></p></td></tr><tr style="height:0pt"><td style="width:56.75pt"></td><td style="width:248.05pt"></td><td style="width:7.1pt"></td><td style="width:55.2pt"></td><td style="width:1.55pt"></td></tr></tbody></table> ```